– Appointment adds oncology and cell therapy clinical development expertise to Board as Company continues late-stage development of its lead CAR T-cell therapy candidate, firi-cel (CRG-022) –
SAN MATEO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced it has appointed Kapil Dhingra, M.B.B.S., to the Company's Board of Directors. Dr. Dhingra is a medical oncologist and a physician-scientist bringing more than 25 years of strategic clinical development experience in oncology, including cell therapy, with a proven track record in drug development, patient care and academic research.
Dr. Dhingra's development experience spans several oncology companies, both as a Board member or in senior leadership. He is currently Chairman of the Board for LAVA Therapeutics, a member of the Board of Supervisors for Servier and a member of the Board of Directors of Black Diamond Therapeutics, Inc., Replimune, Inc., and Median Technologies. He previously served on the Board of Autolus Therapeutics plc from the company's inception until the recent Biologics License Application (BLA) filing of its CAR T-cell therapy.
"We are pleased to welcome Dr. Dhingra to our Board," said Gina Chapman, President and Chief Executive Officer, CARGO Therapeutics. "As a veteran clinical oncology leader with demonstrated experience in cell therapy development and expertise in bringing new therapeutics through the clinic to commercialization, his guidance will prove especially valuable as we advance our lead candidate firi-cel and a pipeline of next generation, potentially curative CAR T-cell therapies."
"CARGO has already made tremendous clinical progress with their differentiated anti-CD22 approach and rapidly enrolling Phase 2 clinical trial in relapsed or refractory large B-cell lymphoma," said Kapil Dhingra, M.B.B.S., member of the Board of Directors, CARGO Therapeutics. "I look forward to contributing to CARGO's continued success as we prioritize developing firi-cel and an exciting pipeline with potential to expand to other B-cell malignancies."
In 2008, Dr. Dhingra founded and continues to be a managing member of KAPital Consulting, LLC, a healthcare consulting firm providing strategic advisory services to biotechnology companies. Previously he served as Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at The Roche Group (Roche), during which he led numerous drug approvals. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company.
Dr. Dhingra has also served as a faculty member at The University of Texas M.D. Anderson Cancer Center, Indiana University School of Medicine and Memorial Sloan Kettering Cancer Center.
— 隨着公司繼續在後期開發其領先的CAR T細胞療法候選藥物firi-cel（CRG-022），該任命爲董事會增加了腫瘤學和細胞療法臨床開發專業知識 —
加利福尼亞州聖馬特奧，2024年4月15日（GLOBE NEWSWIRE）——CARGO Therapeutics, Inc.（納斯達克股票代碼：CRGX）是一家臨床階段的生物技術公司，旨在爲癌症患者推進下一代可能具有治療作用的細胞療法，今天宣佈已任命工商管理碩士卡皮爾·丁格拉爲公司董事會成員。Dhingra博士是一名腫瘤內科醫生和醫生兼科學家，在腫瘤學（包括細胞療法）領域擁有超過25年的戰略臨床開發經驗，在藥物開發、患者護理和學術研究方面有着良好的記錄。
Dhingra博士的開發經驗跨越了多家腫瘤公司，無論是董事會成員還是高級領導層。他目前是LAVA Therapeutics董事會主席、Servier監事會成員以及黑鑽療法公司、Replimune, Inc.和Median Technologies的董事會成員。從Autolus Therapeutics plc成立到最近提交其CAR T細胞療法的生物製劑許可申請（BLA），他曾在該公司董事會任職。
CARGO Therapeutics總裁兼首席執行官吉娜·查普曼說：“我們很高興歡迎丁格拉博士加入我們的董事會。”“作爲一位資深的臨床腫瘤學領導者，他在細胞療法開發方面擁有豐富的經驗，在將新療法通過臨床推向商業化方面擁有專業知識，他的指導將證明在我們推進主要候選藥物firi-cel和下一代可能具有治療性的CAR T細胞療法管道時特別有價值。”
CARGO Therapeutics董事會成員卡皮爾·丁格拉說：“CARGO憑藉其差異化的抗CD22方法和迅速註冊復發或難治性大B細胞淋巴瘤的2期臨床試驗，已經取得了巨大的臨床進展。”“我期待爲CARGO的持續成功做出貢獻，因爲我們將優先開發firi-cel和一條有可能擴展到其他B細胞惡性腫瘤的令人興奮的產品線。”
2008年，丁格拉博士創立了Kapital Consulting, LLC並繼續擔任其管理成員。Kapital Consulting, LLC是一家爲生物技術公司提供戰略諮詢服務的醫療保健諮詢公司。此前，他曾在羅氏集團（Roche）擔任腫瘤疾病生物學領導團隊負責人和腫瘤學臨床開發主管，在此期間，他領導了多項藥物的批准。在加入羅氏之前，他在禮來公司的腫瘤學臨床開發小組工作。
丁格拉博士還曾在德克薩斯大學安德森醫學博士癌症中心、印第安納大學醫學院和紀念斯隆·凱特琳癌症中心擔任教員。
